MORPHOTEK, INC.

Oct 12, 06
	NEW STORY
11:12 ET	Morphotek Raises $40 Million to Advance Its Antibody Pipeline
Aug 30, 06
12:44 ET	European Patent Office Grants Morphotek Two Technology Patents
Jun 21, 06
16:13 ET	Morphotek Announces Orphan Drug Status Granted for MORAb-003, A Monoclonal Antibody for the Treatment of Ovarian Cancer
Jun 08, 06
12:00 ET	Morphotek Announces Initiation of Phase II Clinical Studies For MORAb-003 in Ovarian Cancer
May 17, 06
08:00 ET	Morphotek Announces Three Presentations on Its Lead Therapeutic Candidates MORAb-003 and MORAb-009 at the 2006 American Society of Clinical Oncology Meeting
Apr 03, 06
08:09 ET	Morphotek Announces Scientific Publications Describing Its Human Antibody Technology and the Biological Role of a Neovascular Therapeutic Target Antigen
Mar 13, 06
16:42 ET	Morphotek Announces Appointments and Promotions to Management Team
Feb 13, 06
12:29 ET	Morphotek Announces FDA Acceptance of the IND for MORAb-009, a Monoclonal Antibody for the Treatment of Mesothelin-Expressing Cancers
Jan 23, 06
09:31 ET	Morphotek Issued U.S. Patent 6,982,169 Covering the Use of Chemical Inhibitors of Mismatch Repair
Jan 09, 06
10:00 ET	Morphotek Announces IND Submission for MORAb-009, a Monoclonal Antibody for the Treatment of Mesothelin-Expressing Cancers
Jan 05, 06
05:00 ET	Morphotek Announces Divestment of Cell Line Optimization and Cell Evolution Service Business to Invitrogen Corporation
Jan 03, 06
15:06 ET	Morphotek Expands Oncology Pipeline With Product Candidate From the National Cancer Institute (NCI)
Nov 14, 05
05:00 ET	Morphotek Announces Collaboration With the John Wayne Cancer Institute for the Development of Antibodies to Treat Melanoma and Lung Cancer
Aug 08, 05
13:41 ET	Morphotek Issued U.S. Patent 6,921,666 for Generating Genetically Evolved Yeast Through the Regulation of Mismatch Repair
Jun 30, 05
11:23 ET	Morphotek and Baxter Extend Development and Clinical Supply Agreement to Support Morphotek's Antibody Pipeline
May 18, 05
15:06 ET	Morphotek Announces Multi-Project, Research, Evaluation and Collaboration Agreement with GlaxoSmithKline
Apr 18, 05
11:07 ET	Morphotek Announces Multi-Year, Research Collaboration Agreement with Amgen to Optimize Expression of Antibodies
Mar 28, 05
17:43 ET	Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003, a Humanized Monoclonal Antibody for the Treatment of Advanced Ovarian Cancer
Mar 09, 05
12:11 ET	William Claypool Joins Morphotek Board of Directors
Jan 31, 05
14:54 ET	Morphotek Receives NCI Funding to Support Development of High Throughput Antibody Dependent Cellular Cytotoxicity Assays to Generate Therapeutic Antibodies
Dec 21, 04
08:03 ET	Morphotek Appoints Senior Vice President of Clinical Development to Advance Therapeutic Antibody Portfolio
Dec 13, 04
08:03 ET	Morphotek Issued U.S. Patent 6,825,038 for Generating Genetically Evolved Mammalian Cells Through the Regulation of Mismatch Repair
Dec 01, 04
09:24 ET	Morphotek Announces Second Research Collaboration and License Agreement with Novo Nordisk to Develop High-Titer Cell Lines for the Scaleable Manufacturing of Therapeutic Antibodies
Nov 17, 04
14:22 ET	Morphotek Honored With Technology Company of the Year Award; The Company Recognized As One of Area's Top Biotechnology Organizations
Nov 15, 04
09:06 ET	Morphotek and SC BioSciences Announce a Business Collaboration for the Marketing of MORPHOTEK's Proprietary Cell Line Evolution Services in Japan
Nov 08, 04
08:06 ET	Morphotek Issued U.S. Patent for Generating Genetically Altered Antibody Producing Cell Lines With Improved Antibody Characteristics
Sep 27, 04
08:05 ET	Morphotek Announces Research and Development Agreement with USAMRIID At Fort Detrick for the Development of Antibodies to Detect and Treat Biowarfare Pathogens
Aug 11, 04
15:38 ET	Morphotek Signs Development and Clinical Supply Agreement With Baxter for Lead Therapeutic Antibody
Aug 10, 04
08:06 ET	Morphotek Signs Development and Clinical Supply Agreement With Baxter for Lead Therapeutic Antibody
Jul 19, 04
08:15 ET	Protein Design Labs and Morphotek Announce Broad, Multi-Year Research Cross- License and Commercialization Agreement
Jun 07, 04
17:29 ET	Morphotek Announces Collaborative Agreement With Tanox to Develop High-Titer Production Cells for the Manufacturing of Therapeutic Antibodies Using Suppressor of Immunoglobulin Product (SIP) Technology
Jun 01, 04
16:54 ET	Morphotek Issued U.S. Patent for Generating Genetically Enhanced Antigens for Vaccine Development
Apr 06, 04
07:02 ET	Morphotek Achieves Collaboration Milestone With the Successful Development of Antibody Cell Line for Centocor
Feb 18, 04
07:02 ET	Morphotek Inc. Closes $26 Million Series C Financing
Jan 12, 04
07:02 ET	Morphotek Announces Research and Development Agreement With the National Cancer Institute For the Development of Antibodies For the Treatment of Pancreatic, Ovarian and Lung Cancer
Dec 16, 03
07:02 ET	Morphotek Announces Successful Development of Antibody Cell Line For Abgenix
Dec 15, 03
01:00 ET	Morphotek Announces Issuance of Broad Patent Covering the Generation of Optimized Yeast Strains for Biotherapeutic and Biological Product Discovery, Development, and Manufacturing
Oct 20, 03
07:03 ET	Morphotek Announces Contract Manufacturing and Development Collaboration Agreement With Baxter Healthcare Corporation
Jul 07, 03
01:00 ET	Morphotek Announces Research Collaboration and License Agreement With Novo Nordisk for Improvements to a Protein Process of a Marketed Therapeutic Protein
Jun 23, 03
07:01 ET	Morphotek Issued Patent 6,576,468 For Platform Technology to Develop Novel Classes of Antimicrobial Agents
Jun 20, 03
07:00 ET	Morphotek Announces Appointments to Scientific Advisory Board
Jan 21, 03
07:04 ET	Morphotek Announces Collaborative Research Agreement With Centocor to Develop a High-Titer Antibody Cell Line for the Manufacturing of a Lead Therapeutic Antibody
Jan 07, 03
09:04 ET	Morphotek Announces Research Agreement With Abgenix to Develop High-Titer Antibody Cell Lines for Manufacturing
Sep 30, 02
17:37 ET	Morphotek Receives Pennsylvania Opportunity Grant to Support Ongoing Research and Development
Sep 26, 02
16:40 ET	Morphotek Announces Delivery of Evolved Cell Line to Wyeth Pharmaceuticals for Target Discovery
Jul 23, 02
16:38 ET	Morphotek Receives Army Grant to Support Development of High Titer Production Strains for the Generation of Therapeutic Polypeptides
Jun 18, 02
15:53 ET	Morphotek Announces the Appointment of Rodney Dausch As Vice President of Finance and Chief Financial Officer
May 23, 02
15:27 ET	Morphotek Expands Operations and Relocates to New Facility in Exton, Pa.
Apr 30, 02
15:53 ET	Morphotek and the Ludwig Institute For Cancer Research Announce Collaborative Research Agreement to Develop Therapeutic Monoclonal Antibodies for The Treatment of Cancer
Mar 27, 02
11:44 ET	Morphotek Receives Ben Franklin Emerging Business Biotech Company of the Year Award
Feb 06, 02
09:07 ET	Morphotek and The Wistar Institute Announce Collaborative Research Agreement On Monoclonal Antibodies
Feb 01, 02
09:56 ET	Morphotek Announces Appointment to Senior Management
Jan 21, 02
10:50 ET	David R. King Joins Morphotek Board of Directors
Sep 27, 01
12:07 ET	Morphotek Announces Collaborative Research Agreement With Wyeth-Ayerst Laboratories
Aug 13, 01
12:44 ET	Morphotek Raises $10 Million in Second Round Financing